202 related articles for article (PubMed ID: 15791457)
21. The involvement of nuclear factor-kappa B in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene.
Konson A; Mahajna JA; Danon A; Rimon G; Agbaria R
Cancer Gene Ther; 2006 Dec; 13(12):1093-104. PubMed ID: 16841079
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
Uwagawa T; Li Z; Chang Z; Xia Q; Peng B; Sclabas GM; Ishiyama S; Hung MC; Evans DB; Abbruzzese JL; Chiao PJ
Cancer; 2007 May; 109(10):2142-53. PubMed ID: 17410536
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition: mechanism of action.
DeMartino GN
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
[TBL] [Abstract][Full Text] [Related]
25. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
[TBL] [Abstract][Full Text] [Related]
26. EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
Baek MK; Kim MH; Jang HJ; Park JS; Chung IJ; Shin BA; Ahn BW; Jung YD
Oncol Rep; 2008 Dec; 20(6):1569-75. PubMed ID: 19020743
[TBL] [Abstract][Full Text] [Related]
27. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?
Suh J; Rabson AB
J Cell Biochem; 2004 Jan; 91(1):100-17. PubMed ID: 14689584
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Wang W; Abbruzzese JL; Evans DB; Chiao PJ
Oncogene; 1999 Aug; 18(32):4554-63. PubMed ID: 10467400
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract][Full Text] [Related]
34. Androgen-mediated resistance to apoptosis.
Coffey RN; Watson RW; O'Neill AJ; Mc Eleny K; Fitzpatrick JM
Prostate; 2002 Dec; 53(4):300-9. PubMed ID: 12430141
[TBL] [Abstract][Full Text] [Related]
35. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
[TBL] [Abstract][Full Text] [Related]
36. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Kamer S; Ren Q; Dicker AP
Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
[TBL] [Abstract][Full Text] [Related]
37. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer.
Mortenson MM; Galante JG; Gilad O; Schlieman MG; Virudachalam S; Kung HJ; Bold RJ
J Cell Biochem; 2007 Dec; 102(5):1171-9. PubMed ID: 17960583
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines.
Parra E; Ferreira J; Ortega A
Int J Oncol; 2011 Aug; 39(2):345-52. PubMed ID: 21617851
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
Goktas S; Baran Y; Ural AU; Yazici S; Aydur E; Basal S; Avcu F; Pekel A; Dirican B; Beyzadeoglu M
Urology; 2010 Apr; 75(4):793-8. PubMed ID: 19800672
[TBL] [Abstract][Full Text] [Related]
40. NF-kappaB in cancer--a friend turned foe.
Ravi R; Bedi A
Drug Resist Updat; 2004 Feb; 7(1):53-67. PubMed ID: 15072771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
